<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05071131</url>
  </required_header>
  <id_info>
    <org_study_id>RESTORE</org_study_id>
    <nct_id>NCT05071131</nct_id>
  </id_info>
  <brief_title>Effect of Inulin on Gut Microbiota and Gut Barrier in Chronic Kidney Disease</brief_title>
  <acronym>RESTORE</acronym>
  <official_title>Investigating the Effect of Inulin on Gut Microbiota and Gut Barrier in Advanced Chronic Kidney Disease - a Randomised, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An adequate fiber intake is crucial for a well-balanced diet and reduces the risk of chronic&#xD;
      diseases. However, nutritional recommendations for chronic kidney disease patients lead to an&#xD;
      insufficient fiber intake with possible maladaptive effects on the gut microbiome. Therefore,&#xD;
      we want to study the effects of a 28-day inulin supplementation on the gut microbiome, gut&#xD;
      barrier function, bacterial metabolites and immune cell states in chronic kidney disease&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of Zonulin-1</measure>
    <time_frame>After 28 days compared to placebo</time_frame>
    <description>Measured by ELISA [ng/ml]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of soluble CD14</measure>
    <time_frame>After 28 days compared to placebo</time_frame>
    <description>Measured by ELISA [ng/ml]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-chain fatty acid-associated bacterial gene expression</measure>
    <time_frame>After 28 days compared to placebo and adjusted for baseline</time_frame>
    <description>Measured by quantitative PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-chain fatty acid-associated gene expression in immune cells</measure>
    <time_frame>After 28 days compared to placebo</time_frame>
    <description>Measured by quantitative PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indole-associated bacterial gene expression</measure>
    <time_frame>After 28 days compared to placebo</time_frame>
    <description>Measured by quantitative PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indole-associated gene expression in immune cells</measure>
    <time_frame>After 28 days compared to placebo</time_frame>
    <description>Measured by quantitative PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal metabolome</measure>
    <time_frame>After 28 days compared to placebo and adjusted for baseline</time_frame>
    <description>Measured by mass spectrometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum metabolome</measure>
    <time_frame>After 28 days compared to placebo</time_frame>
    <description>Measured by mass spectrometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of Trimethylamine-N-Oxide (TMAO)</measure>
    <time_frame>After 28 days compared to placebo</time_frame>
    <description>Measured by LC-MS [µM]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal microbiome taxonomy</measure>
    <time_frame>After 28 days compared to placebo</time_frame>
    <description>Measured by 16S amplicon sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activation potential of aryl hydrocarbon receptor (AhR) in serum</measure>
    <time_frame>After 28 days compared to placebo and adjusted for baseline</time_frame>
    <description>Measured by cell-based luciferase reporter assay (delta luminescence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of circulating T-cell subtypes</measure>
    <time_frame>After 28 days compared to placebo</time_frame>
    <description>Measured by flow cytometry (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Office systolic blood pressure</measure>
    <time_frame>After 28 days compared to placebo</time_frame>
    <description>Mean of five consecutive blood pressure measurements (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Office diastolic blood pressure</measure>
    <time_frame>After 28 days compared to placebo</time_frame>
    <description>Mean of five consecutive blood pressure measurements (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of IL-1</measure>
    <time_frame>After 28 days compared to placebo</time_frame>
    <description>Measured by ELISA [pg/ml]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of IL-6</measure>
    <time_frame>After 28 days compared to placebo</time_frame>
    <description>Measured by ELISA [pg/ml]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of TNF-alpha</measure>
    <time_frame>After 28 days compared to placebo</time_frame>
    <description>Measured by ELISA [pg/ml]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>After 28 days compared to placebo</time_frame>
    <description>Creatine serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystatin c</measure>
    <time_frame>After 28 days compared to placebo</time_frame>
    <description>Cystatin c serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine / cystatin c ratio</measure>
    <time_frame>After 28 days compared to placebo</time_frame>
    <description>Measured in serum</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Kidney Disease 5D</condition>
  <arm_group>
    <arm_group_label>Inulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 grams inulin per day for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 grams maltodextrin per day for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Inulin</intervention_name>
    <description>2 sachets à 15 grams daily for 28 days</description>
    <arm_group_label>Inulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 sachets à 15 grams daily for 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women in a ratio of 1:1&#xD;
&#xD;
          -  Body mass index 18.5 - 34.9 kg/m^2&#xD;
&#xD;
          -  End-stage kidney disease, which has been treated regularly with hemodialysis for at&#xD;
             least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Malignant diseases&#xD;
&#xD;
          -  Recent or current hospitalization&#xD;
&#xD;
          -  Postoperative phase&#xD;
&#xD;
          -  Acute infections&#xD;
&#xD;
          -  Malnutrition&#xD;
&#xD;
          -  Antibiotic treatment within the last 4 weeks&#xD;
&#xD;
          -  Regular intake of probiotics and/or prebiotics&#xD;
&#xD;
          -  Change of body weight of more than 2 kg in the month prior to study entry&#xD;
&#xD;
          -  Known drug or alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anja Mähler, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicola Wilck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victoria McParland, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johannes Holle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Victoria McParland, PhD</last_name>
    <phone>+49 30 450 540 464</phone>
    <email>victoria.mcparland@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Experimental and Clinical Research Center</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Victoria McParland, PhD</last_name>
      <phone>+4930450540464</phone>
      <email>victoria.mcparland@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Nicola Wilck, MD</last_name>
      <phone>+4930450540459</phone>
      <email>nicola.wilck@charite.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Anja Maehler</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>Fiber</keyword>
  <keyword>Zonulin</keyword>
  <keyword>Short chain fatty acids</keyword>
  <keyword>Dietary analysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results of reported articles (text, tables, figures, supplemental data) will be shared after deidentification.</ipd_description>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication.</ipd_time_frame>
    <ipd_access_criteria>Researchers who provide a methodologically sound proposal.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

